Abstract:Dougho Park, 1, 2 Hyoung Seop Kim, 3 Jong Hun Kim 4 1 Medical Research Institute, Pohang Stroke and Spine Hospital, Pohang, Republic of Korea; 2 Department of Medical Science and Engineering, School of Convergence Science and Technology, Pohang University of Science and Technology, Pohang, Republic of Korea; 3 Department of Physical Medicine and Rehabilitation, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea; 4 Department of Neurology, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea Correspondence: Jong Hun Kim, Department of Neurology, National Health Insurance Service Ilsan Hospital, 100 Ilsan-ro, Goyang, 10444, Republic of Korea, Tel +82-31-900-0213, Fax +82-31-900-0343, Email Purpose: Clinical studies on dysbiosis and stroke outcomes has been insufficient to establish clear evidence. This study aimed to investigate the effects of pre-antibiotic use before a stroke event on secondary outcomes using a longitudinal population-level database. Patients and Methods: This retrospective cohort study included adults aged 55 years or older diagnosed with acute ischemic stroke (AIS) and acute hemorrhagic stroke (AHS) between 2004 and 2007. Patients were followed-up until the end of 2019, and the target outcomes were secondary AIS, AHS, and all-cause mortality. Multivariable Cox regression analyses were applied, and we adjusted covariates such as age, sex, socioeconomic status, hypertension, diabetes, and dyslipidemia. Pre-antibiotic use was identified from 7 days to 1 year before the acute stroke event. Results: We included 159,181 patients with AIS (AIS group) and 49,077 patients with AHS (AHS group). Pre-antibiotic use significantly increased the risk of secondary AIS in the AIS group (adjusted hazard ratio [aHR], 1.03; 95% confidence interval [CI], 1.01– 1.05; p = 0.009) and secondary AHS in the AHS group (aHR, 1.08; 95% CI, 1.03– 1.12; p < 0.001). Furthermore, pre-antibiotic use in the AIS group was associated with a lower risk of mortality (aHR, 0.95; 95% CI, 0.94– 0.96; p < 0.001). Conclusion: Our population-based longitudinal study revealed that pre-antibiotic use was associated with a higher risk of secondary stroke and a lower risk of mortality in the AIS and AHS groups. Further studies are needed to understand the relationship between dysbiosis and stroke outcomes. Keywords: brain-gut axis, dysbiosis, mortality, stroke The gut houses trillions of microorganisms, collectively known as the gut microbiome. 1 Dysbiosis, also known as antibiotic scars, occurs when antibiotic overuse leads to the destruction of beneficial bacteria in the gut. 2 Beneficial bacteria help to regulate the immune system, digest food, and produce essential vitamins and nutrients. When antibiotics are administered, they can disrupt the balance of the gut microbiome, leading to the overgrowth of harmful bacteria and the reduction of beneficial bacteria. 3 Dysbiosis represents wide-ranging and varied symptoms depending on the severity of the damage to the gut microbiome, and it can lead to health problems such as inflammatory autoimmune diseases, allergies, cancer, cardiovascular diseases, and stroke. 4,5 The gut-brain axis is a bidirectional communication system that allows the gut and brain to influence each other's functions. 6 Several different pathways, including the nervous, immune, and endocrine systems, mediate the gut-brain axis. 7 Studies have revealed that the occurrence and severity of acute ischemic stroke (AIS) and acute hemorrhagic stroke (AHS) could affect dysbiosis in patients and rodents. 8 Inflammation is a key factor in the development of AIS, 9,10 and the gut microbiome regulates inflammation in the body. 11 Previous studies have shown that individuals with a diverse and balanced gut microbiome have lower levels of inflammation than those with an imbalance in gut bacteria. 12 High blood pressure is another major risk factor for AIS and AHS. The gut microbiome plays a role in regulating blood pressure, 13 and studies have shown that certain types of gut bacteria can produce compounds that can help lower blood pressure. 14 Cholesterol levels are also linked to the gut microbiome; studies have reported that individuals with higher levels of certain types of gut bacteria had lower cholesterol levels, which could help reduce the risk of AIS. 15,16 Overall, the gut microbiome plays a vital role in the development and prognosis of primary and secondary acute stroke. However, more research is needed to fully understand the relationship between the gut microbiome and str -Abstract Truncated-

Effects of long-term regular oral aspirin combined with atorvastatin to prevent ischemic stroke on human gut microbiota

Dysbiosis of Gut Microbiota With Reduced Trimethylamine-N-Oxide Level in Patients With Large-Artery Atherosclerotic Stroke or Transient Ischemic Attack.

Therapeutic Effects Of Aspirin Combined With Atorvastatin On Ischemic Strokes

IDDF2019-ABS-0188 Gut Microbiota Modulates the Chemopreventive Efficacy of Aspirin on Colorectal Cancer Through Impact on Aspirin Bioavailability

Effects of Losartan, Atorvastatin, and Aspirin on Blood Pressure and Gut Microbiota in Spontaneously Hypertensive Rats

Atorvastatin alleviates microglia-mediated neuroinflammation via modulating the microbial composition and the intestinal barrier function in ischemic stroke mice

Bidirectional effects of oral anticoagulants on gut microbiota in patients with atrial fibrillation

The preliminary evidence on the association of the gut microbiota with stroke risk stratification in South Chinese population

Comparative studies on the effects of different doses of atorvastatin combined with aspirin on inflammatory cytokines and carotid plaques in patients with ischemic cerebrovascular disease

The Effects of Aspirin Intervention on Inflammation-Associated Lingual Bacteria: A Pilot Study from a Randomized Clinical Trial

Aspirin ameliorates atherosclerotic immuno-inflammation through regulating the Treg/Th17 axis and CD39-CD73 adenosine signaling via remodeling the gut microbiota in ApoE-/- mice

Characterization of gut microbiota in adults with coronary atherosclerosis

Effects of Atorvastatin and Aspirin on the Levels of Plasma Lysophospholipids and the Incidence of Stroke in Patients with Atrial Fibrillation

Aspirin Reduces Colorectal Tumor Development in Mice and Gut Microbes Reduce Its Bioavailability and Chemopreventive Effects.

Specific gut microbiome signatures predict the risk of acute ischemic stroke

Effect of Pre-Antibiotic Use Before First Stroke Incidence on Recurrence and Mortality: A Longitudinal Study Using the Korean National Health Insurance Service Database

Probiotics combined with atorvastatin administration in the treatment of hyperlipidemia: A randomized, double-blind, placebo-controlled clinical trial

Identifying gut microbiota with high specificity for ischemic stroke with large vessel occlusion

Analysis of gut microbiota in patients with acute myocardial infarction by 16S rRNA sequencing

Metagenomic analysis of the gut microbiome in atherosclerosis patients identify cross-cohort microbial signatures and potential therapeutic target

Two-sample Mendelian randomization to study the causal association between gut microbiota and atherosclerosis